Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or persistent endometrial cancer.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase II Evaluation of Flavopiridol (NSC# 649890) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|
|Study Start Date:||July 2001|
|Study Completion Date:||February 2006|
- Determine the antitumor activity of flavopiridol in patients with recurrent or persistent endometrial carcinoma.
- Determine the nature and degree of toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 10-24 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00023894
Show 54 Study Locations
|Study Chair:||Edward C. Grendys, MD||Robert H. Lurie Cancer Center|